- Home
- PHVS vs XOMAP Comparison
PHVS vs XOMAP Comparison
Compare PHVS & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- XOMAP
- Stock Information
- Founded
- PHVS 2015
- XOMAP N/A
- Country
- PHVS Switzerland
- XOMAP United States
- Employees
- PHVS N/A
- XOMAP 13
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- XOMAP Health Care
- Exchange
- PHVS Nasdaq
- XOMAP Nasdaq
- Market Cap
- PHVS 980.3M
- XOMAP N/A
- IPO Year
- PHVS 2021
- XOMAP N/A
- Fundamental
- Price
- PHVS $17.51
- XOMAP $25.92
- Analyst Decision
- PHVS Buy
- XOMAP
- Analyst Count
- PHVS 6
- XOMAP 0
- Target Price
- PHVS $37.17
- XOMAP N/A
- AVG Volume (30 Days)
- PHVS 43.8K
- XOMAP N/A
- Earning Date
- PHVS 08-13-2025
- XOMAP N/A
- Dividend Yield
- PHVS N/A
- XOMAP N/A
- EPS Growth
- PHVS N/A
- XOMAP N/A
- EPS
- PHVS N/A
- XOMAP N/A
- Revenue
- PHVS N/A
- XOMAP N/A
- Revenue This Year
- PHVS N/A
- XOMAP N/A
- Revenue Next Year
- PHVS N/A
- XOMAP N/A
- P/E Ratio
- PHVS N/A
- XOMAP N/A
- Revenue Growth
- PHVS N/A
- XOMAP N/A
- 52 Week Low
- PHVS $11.51
- XOMAP N/A
- 52 Week High
- PHVS $25.50
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- PHVS 52.74
- XOMAP 55.43
- Support Level
- PHVS $16.78
- XOMAP $25.66
- Resistance Level
- PHVS $17.53
- XOMAP $25.96
- Average True Range (ATR)
- PHVS 0.98
- XOMAP 0.06
- MACD
- PHVS 0.00
- XOMAP 0.02
- Stochastic Oscillator
- PHVS 41.59
- XOMAP 88.89
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.